Discover Camcevi. 99th Annual Western Section AUA Meeting, October 1-5, 2023, Lake Tahoe
Discover Camcevi. UroGPO UNIO Member Summit, October 5-7, 2023, Redondo Beach, CA
site-logo
AVAILABLE
TO ORDER
 

This site is intended for use by U.S. residents only.

©2023 CAMCEVI. All rights reserved. WS-CAM-2200004

SYRINGE ASSEMBLY

Prefilled with no mixing required, CAMCEVI simplifies syringe prep.1

 

REMOVE

Remove

Remove CAMCEVI kit from refrigerator. Open carton and remove blister. Allow to sit at room temperature for 30 minutes.1

INSPECT

Inspect

Examine all contents of the packaging. Do not use if package contents are damaged or syringe is expired.1

PREPARE

Prepare

Wearing gloves, remove syringe and needle cartridge from blister carton and place on clean, dry surface.1

ASSEMBLE

Assemble

Remove gray cap from syringe. Twist clear cap off bottom of needle cartridge. Attach needle to end of syringe by pushing and turning needle until firmly connected to syringe.1

Watch and learn to prepare, assemble and administer CAMCEVI

video-preview of Guide to assemble Syringe
syringe normal

CAMCEVI must be administered by a healthcare provider.

Syringe animation
Syringe animation

STORAGE1

Store CAMCEVI at 36ºF–46ºF (2°C–8°C)1

Protect CAMCEVI from light by storing in the original package until time of use1

Do not freeze or shake1

Syringe tip and plunger stopper are latex free1

DelMay_Camcevi_Nurse

Injection Sites

Injection Sites
Injection Sites

SUB-Q ADMINISTRATION

Choose an injection site in the upper- or mid-abdominal area with sufficient soft or loose subcutaneous tissue that has not been used recently.1

About Dosing

PROVEN LEUPROLIDE EFFICACY

CAMCEVI offers proven leuprolide efficacy in a convenient prefilled, no-mix syringe.1

See the results

ADDITIONAL RESOURCES
AND SUPPORT

Access useful resources, information, and more for you and your patients.

See all resources

SIMPLE
ORDERING

Order CAMCEVI through your distribution and GPO partners.

Learn more

HAVE A QUESTION?

Let us simplify it for you.

CONNECT WITH A REPRESENTATIVE

    GET UPDATES

    Stay informed about
    CAMCEVI with regular updates,
    education, and more.

    *Required fields

    IMPORTANT SAFETY INFORMATION

    Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.

    CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction, spinal cord compression, have been observed, which may contribute to paralysis with or without fatal complications.

    Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

    Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.

    Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and according to current clinical practice.

    Androgen deprivation therapy may prolong the QT interval. Consider periodic monitoring of electrocardiograms and electrolytes.

    Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.

    Monitor serum levels of testosterone following injection of CAMCEVI.

    Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.

    The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.

    INDICATION

    CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.

    Click here for full Prescribing Information.

    Reference:

    1. CAMCEVI. Prescribing information. Accord BioPharma; May 2021.